Inhibition of Bruton Tyrosine Kinase by Acalabrutinib Reduces cGVHD
Overview
Acalabrutinib, a selective BTK inhibitor, significantly improves survival and clinical outcomes in murine models of sclerodermatous chronic graft-versus-host disease (cGVHD). The treatment reduces skin pathology and inflammatory mediator levels, suggesting a potential therapeutic role in cGVHD management.
Background
Chronic graft-versus-host disease (cGVHD) is a major complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT), affecting patient morbidity and mortality. The pathogenesis of cGVHD involves alloreactive B- and T-cells, with Bruton tyrosine kinase (BTK) playing a crucial role in B-cell receptor signaling. Targeting BTK may provide a novel therapeutic approach to mitigate cGVHD.
Data Highlights
Outcome
Acalabrutinib Group
Control Group
Survival Rate
Improved
Lower
Clinical cGVHD Scores
Better
Worse
Dermal Thickness
Reduced
Increased
Mast Cell Numbers
Decreased
Increased
Key Findings
Acalabrutinib treatment improved survival rates in murine models of cGVHD.
Clinical cGVHD scores were significantly better in the acalabrutinib-treated group.
Skin pathology, including dermal thickness and fibrosis, was reduced with acalabrutinib treatment.
Inhibition of mast cell activation and pro-inflammatory chemokines was observed in vitro.
RNA sequencing revealed downregulation of keratinization-related genes with treatment.
Clinical Implications
The findings suggest that acalabrutinib may be a promising therapeutic option for patients with sclerodermatous cGVHD, potentially improving clinical outcomes and reducing disease severity. Further clinical investigations are warranted to evaluate its efficacy in human subjects.
Conclusion
Acalabrutinib demonstrates significant potential in ameliorating sclerodermatous cGVHD in murine models, warranting further exploration in clinical settings.
by Vasantharaja Raguraman, Miranda Mysinger, Mohit Verma, Shanid Mohiyuddin, Nashwan Jabbour, Melissa Kesler, Trupti Joshi, Senthilnathan Palaniyandi, Gerhard C. Hildebrandt
